Leukocyte protein calprotectin and outcome in rheumatoid arthritis

References

• Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113–23.
   PubMedGoogle Scholar
• Garred P, Fosse E, Fagerhol MK, Videm V, Mollnes TE. Calprotectin and complement activation during major operations with or without cardiopulmonary bypass. Ann Thorac Surg 1993;55:694–9.
   Google Scholar
• Berntzen HB, Munthe E, Fagerhol MK. The major leukocyte protein Li as an indicator of inflammatory joint disease. Scand J Rheumatol 1988;17 Suppl 76:251–6.
   Google Scholar
• Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980;16:27 3–82.
   Google Scholar
• Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte Li protein, calprotectin. Lancet 1990;336:76 3–5.
   Google Scholar
• Heyden A, Thrane PS, Brandtzaeg P. Loss of epithelial Li expression is associated with cellular invasion of oral squamous cell carcinomas. J Oral Pathol Med 1992;21:33 0–5.
   Google Scholar
• Brandtzaeg P, Gabrielsen TO, Dale I, Muller F, Steinbakk M, Fagerhol MK. The leucocyte protein Li (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv Exp Med Biol 1995;371A:20 1–6.
   Google Scholar
• Murthy AR, Lehrer RI, Harwig SS, Miyasaki KT. In vitro candidastatic properties of the human neutrophil calprotectin complex. J Immunol 1993;151:629 1–301.
   PubMed Web of Science ®Google Scholar
• Sohnle PG, Hahn BL, Santhanagopalan V. Inhibition of Candida albicans growth by calprotectin in the absence of direct contact with the organisms. J Infect Dis 1996; 174:1369–72.
   Google Scholar
• Brun JG, Haland G, Haga HJ, Fagerhol MK, Jonsson R. Effects of calprotectin in avridine-induced arthritis. APMIS 1995;103:23 3–40. H. Roth J, Goebeler M, Sorg C. S100A8 and S100A9 in inflammatory diseases. Lancet 2001;357: 1041 .
   Google Scholar
• Brydon WG, Campbell SS, Anderson NA, Wilson RG, Ghosh S. Faecal calprotectin levels and colorectal neoplasia. Gut 200i;48:579–80.
   Google Scholar
• Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001;36:29 1–6.
   Google Scholar
• Golden BE, Clohessy PA, Russell G, Fagerhol MK. Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child 1996;74:13 6–9.
   Google Scholar
• Welle I, Bakke PS, Eide GE, Fagerhol MK, Omenaas E, Gulsvik A. Increased circulating levels of alphal-antitrypsin and calprotection are associated with reduced gas diffusion in the lungs. Eur Respir J 2001;17:110 5–11.
   Google Scholar
• Haspel J, Friedlander DR, Ivgy-May N, et al. Critical and optimal Ig domains for promotion of neurite outgrowth by Li/Ng-CAM. J Neurobiol 2000;42:287–302.
   Google Scholar
• Willard KE, Thorsrud AK, Munthe E, Jellum E. Two-dimensional electrophoretic analysis of human leukocyte proteins from patients with rheumatoid arthritis. Clin Chem 1982;28:106 7–73.
   Google Scholar
• Emery P, Lopez AF, Burns GF, Vadas MA. Synovial fluid neutrophils of patients with rheumatoid arthritis have membrane antigen changes that reflect activation. Ann Rheum Dis 1988;47:3 4–9.
   Google Scholar
• Berntzen HB, Olmez U, Fagerhol MK, Munthe E. The leukocyte protein Li in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991;20:7 4–82.
   Google Scholar
• Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leukocyte protein Li as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989;16:141 6–20.
   Google Scholar
• Brun JG, Haga HJ, Boe E, et al. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol 1992;19:85 9–62.
   Google Scholar
• Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol 1994;21:73 3–8.
   Google Scholar
• Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000;39:24–9.
   PubMed Web of Science ®Google Scholar
• Combe B, Dougados M, Goupille P, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multi-parameter prospective study. Arthritis Rheum 2001; 44:i736–43.
   Web of Science ®Google Scholar
• Berntzen HB, Fagerhol MK, Ostensen M, Mowinckel P, Hoyeraal HM. The Li protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol 1991;18:13 3–8.
   Google Scholar
• Hammer HB, Kvien TK, Glennas A, Melby K. A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol 1995;13:5 9–64.
   Google Scholar
• Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M, Hughes GR. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus i993;2:47–S0.
   Google Scholar
• Cuida M, Halse AK, Johannessen AC, Tynning T, Jonsson R. Indicators of salivary gland inflammation in primary Sjogren's syndrome. Eur J Oral Sci 1997;105:22 8–33.
   Google Scholar
• Wolfe F, Cush JJ, O'Dell JR, et al. Consensus recommenda-tions for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001;28:142 3–30.
   Google Scholar
• Williamson AA, McColl GJ. Early rheumatoid arthritis: can we predict its outcome? Intern Med J 2001;31:16 8–80.
   Google Scholar
• Brun JG, Ulvestad E, Fagerhol MK, Jonsson R. Effects of human calprotectin (L1) on in vitro immunoglobulin syn-thesis. Scand J Immunol i994;40:675–80.
   Google Scholar
• Murao S, Collart FR, Huberman E. A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J Biol Chem 1989;264:835 6–60.
   Google Scholar
• Isaksen B, Fagerhol MK. Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Mol Pathol 2001;54:28 9–92.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:31 5–24.
   Google Scholar
• Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:13 7–45.
   Google Scholar
• Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol 2000;35:6 4–9.
   Google Scholar
• Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977;18:48 1–91.
   Google Scholar
• Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:200 9–17.
   Google Scholar
• Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000;43:275 1–61.
   PubMed Web of Science ®Google Scholar
• Coste J, Spira A, Clerc D, Paolaggi JB. Prediction of articular destruction in rheumatoid arthritis: disease activity markers revisited. J Rheumatol i997;24:28–34.
   Google Scholar
• Fuchs HA, Pincus T. Radiographic damage in rheumatoid arthritis: description by nonlinear models. J Rheumatol 1992;19:165 5–8.
   Google Scholar